Who We Are:
Our vision is to enable and support outstanding basic and translational neuroscience research through innovative and affordable products. We are a neurotechnology company established in 2016 as a spin-off from Dr. Frohlich's lab to commercialize XCSITE 100. XCSITE 100 was a research device designed to address concerns about the limited functionality of then available devices to perform gold-standard research studies (randomized, double-blind, placebo-controlled study designs).
Pulvinar Neuro was acquired in 2022 and today is a wholly owned subsidiary of Electromedical Products International, Inc. (EPI). EPI is a privately held, SBIR-eligible medical device manufacturer and is a leader in non-invasive brain stimulation for psychiatric disorders. With the support of EPI and our continued grant support from NIMH and NIDA, we are not only supporting the research community with new tools, but we are also developing our own innovative therapeutics to address some of the most pressing challenges in mental health.
Our vision is to enable and support outstanding basic and translational neuroscience research through innovative and affordable products. We are a neurotechnology company established in 2016 as a spin-off from Dr. Frohlich's lab to commercialize XCSITE 100. XCSITE 100 was a research device designed to address concerns about the limited functionality of then available devices to perform gold-standard research studies (randomized, double-blind, placebo-controlled study designs).
Pulvinar Neuro was acquired in 2022 and today is a wholly owned subsidiary of Electromedical Products International, Inc. (EPI). EPI is a privately held, SBIR-eligible medical device manufacturer and is a leader in non-invasive brain stimulation for psychiatric disorders. With the support of EPI and our continued grant support from NIMH and NIDA, we are not only supporting the research community with new tools, but we are also developing our own innovative therapeutics to address some of the most pressing challenges in mental health.
|
|
Questions?Contact us via email.
|